William W Carroll1, Rodney J Schlosser1,2, Brendan P O'Connell1, Zachary M Soler1, Jennifer K Mulligan1,2,3. 1. Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC. 2. Ralph H. Johnson VA Medical Center, Charleston, SC. 3. Department of Pediatrics, Medical University of South Carolina, Charleston, SC.
Abstract
BACKGROUND: Vitamin D3 (VD3) is a steroid hormone with known antiproliferative properties. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have been shown to be VD3-deficient. Moreover, VD3 deficiency is associated with worse disease in patients with CRSwNP. One cell type thought to play a role in chronic rhinosinusitis (CRS) is the human sinonasal fibroblast (HSNF). The aim of this study was to investigate VD3 deficiency and HSNF proliferation in CRSwNP. METHODS: Blood and sinus tissue explants were collected at the time of surgery from patients with CRSwNP (n = 15). Control subjects (n = 12) were undergoing surgery for cerebrospinal fluid leak repair or to remove non-hormone-secreting pituitary tumors. Ex vivo HSNF proliferation was analyzed with flow cytometry using expression of fibroblast-specific protein (FSP) and the proliferation marker Ki67. Plasma levels of 25-hydroxyvitamin D3 (25VD3) were measured by enzyme-linked immunosorbent assay. In vitro analysis of HSNF proliferation after treatment with calcitriol (1,25VD3) was performed using carboxyfluorescein succinimidyl ester (CFSE) and analyzed with flow cytometry. RESULTS: In CRSwNP patients there was an inverse correlation between 25VD3 and proliferating HSNFs (p = 0.0135). This correlation was not seen for control patients (p = 0.3869). In vitro analysis showed that HSNFs from patients with CRSwNP had a higher proliferation index at baseline than HSNFs from control patients (p < 0.01). When treated with 1,25VD3, there was a significant decrease in HSNF proliferation index in patients with CRSwNP (p < 0.01), but not control patients. CONCLUSION: VD3 deficiency is associated with increased HSNF proliferation in CRSwNP. Further investigation into how HSNFs and VD3 impact CRSwNP pathophysiology is warranted.
BACKGROUND:Vitamin D3 (VD3) is a steroid hormone with known antiproliferative properties. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have been shown to be VD3-deficient. Moreover, VD3 deficiency is associated with worse disease in patients with CRSwNP. One cell type thought to play a role in chronic rhinosinusitis (CRS) is the human sinonasal fibroblast (HSNF). The aim of this study was to investigate VD3 deficiency and HSNF proliferation in CRSwNP. METHODS: Blood and sinus tissue explants were collected at the time of surgery from patients with CRSwNP (n = 15). Control subjects (n = 12) were undergoing surgery for cerebrospinal fluid leak repair or to remove non-hormone-secreting pituitary tumors. Ex vivo HSNF proliferation was analyzed with flow cytometry using expression of fibroblast-specific protein (FSP) and the proliferation marker Ki67. Plasma levels of 25-hydroxyvitamin D3 (25VD3) were measured by enzyme-linked immunosorbent assay. In vitro analysis of HSNF proliferation after treatment with calcitriol (1,25VD3) was performed using carboxyfluorescein succinimidyl ester (CFSE) and analyzed with flow cytometry. RESULTS: In CRSwNP patients there was an inverse correlation between 25VD3 and proliferating HSNFs (p = 0.0135). This correlation was not seen for control patients (p = 0.3869). In vitro analysis showed that HSNFs from patients with CRSwNP had a higher proliferation index at baseline than HSNFs from control patients (p < 0.01). When treated with 1,25VD3, there was a significant decrease in HSNF proliferation index in patients with CRSwNP (p < 0.01), but not control patients. CONCLUSION: VD3 deficiency is associated with increased HSNF proliferation in CRSwNP. Further investigation into how HSNFs and VD3 impact CRSwNP pathophysiology is warranted.
Authors: Laurent Benayoun; Anne Druilhe; Marie-Christine Dombret; Michel Aubier; Marina Pretolani Journal: Am J Respir Crit Care Med Date: 2003-01-16 Impact factor: 21.405
Authors: Alkis J Psaltis; Rodney J Schlosser; James R Yawn; Oswaldo Henriquez; Jennifer K Mulligan Journal: Int Forum Allergy Rhinol Date: 2013-05-02 Impact factor: 3.858
Authors: Jennifer K Mulligan; David R White; Eric W Wang; S Ritter Sansoni; Helen Moses; Robert J Yawn; Carol Wagner; Sarah E Casey; Ryan M Mulligan; Rodney J Schlosser Journal: Otolaryngol Head Neck Surg Date: 2012-05-24 Impact factor: 3.497
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinol Suppl Date: 2012-03
Authors: D D Dean; Z Schwartz; J Schmitz; O E Muniz; Y Lu; F Calderon; D S Howell; B D Boyan Journal: Connect Tissue Res Date: 1996 Impact factor: 3.417
Authors: I Ohno; H Ohtani; Y Nitta; J Suzuki; H Hoshi; M Honma; S Isoyama; Y Tanno; G Tamura; K Yamauchi; H Nagura; K Shirato Journal: Am J Respir Cell Mol Biol Date: 1997-03 Impact factor: 6.914
Authors: M Fraczek; B Rostkowska-Nadolska; D Kusmierz; A Zielinska; J Rok; E Sliupkas-Dyrda; A Grzanka; T Krecicki; M Latocha Journal: Adv Med Sci Date: 2012 Impact factor: 3.287
Authors: Jennifer K Mulligan; Dianna Nord; Maria V Villanueva; Jeb Justice; Brian Lobo; Rodney J Schlosser; Carl Atkinson Journal: J Immunol Date: 2022-07-06 Impact factor: 5.426
Authors: Robert J Taylor; Rodney J Schlosser; Zachary M Soler; Jose L Mattos; Jennifer K Mulligan Journal: Int Forum Allergy Rhinol Date: 2018-05-02 Impact factor: 3.858
Authors: Jennifer K Mulligan; Whitney N Pasquini; William W Carroll; Tucker Williamson; Nicholas Reaves; Kunal J Patel; Elliott Mappus; Rodney J Schlosser; Carl Atkinson Journal: PLoS One Date: 2017-10-18 Impact factor: 3.240